Every day, our experts search for new discoveries and push scientific boundaries in our efforts to deliver powerful medicines for some of the greatest medical challenges. More
12/19/2014 - Cubist Announces FDA Approval of New Antibiotic ZERBAXA™ (Ceftolozane/Tazobactam) for Complicated Urinary Tract and Complicated Intra-abdominal Infections
At Cubist, our culture is our foundation. We share a passion for learning, collaborating, innovating, and most of all, making a difference in people’s lives.
Effective January 22, 2015, Cubist Pharmaceuticals is now a wholly owned subsidiary of Merck & Co., Inc.
Investigator Initiated and Antimicrobial Stewardship Research Grant Applicants: Please follow this link to continue to access Cubist Pharmaceutical’s Research Grant Application and Management system.
Educational Grants & Sponsorship grant Applicants: Please follow this link to continue to access Cubist Pharmaceutical’s Request Management system.